Importantly for the treatment of ROSAH syndrome, DF-003 was also able to suppress ALPK1[T237M] activity in biochemical and cell-based assays. The gene discussed is ALPK1; the disease is retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome.